以纵隔占位首发表现的孤立性髓系肉瘤1例

杨景晖, 周青梅, 尹雪蓉, 姚翔媚, 许欣雨, 袁琳, 胡莹, 李天鹤, 汤春辉

中国当代儿科杂志 ›› 2026, Vol. 28 ›› Issue (3) : 346-352.

PDF(2549 KB)
HTML
PDF(2549 KB)
HTML
中国当代儿科杂志 ›› 2026, Vol. 28 ›› Issue (3) : 346-352. DOI: 10.7499/j.issn.1008-8830.2505032
病例报告

以纵隔占位首发表现的孤立性髓系肉瘤1例

作者信息 +

A case of isolated myeloid sarcoma initially presenting as a mediastinal mass

Author information +
文章历史 +

摘要

患儿,男,7岁,因颜面部水肿入院。超声检查提示中等量心包积液及胸腔积液,胸部电子计算机断层扫描可见纵隔内结构不清,增强扫描呈轻-中度强化,考虑纵隔占位。进一步行全身正电子发射断层显像-计算机断层扫描、纵隔病灶病理活检、胸腔积液及心包积液病理细胞学检查及免疫组化等检查,最终诊断为孤立性髓系肉瘤。病理检查是临床诊断的金标准,但在取材部位受限时,易出现漏诊、误诊,应根据病情多次多部位取材,同时结合流式细胞学及免疫组化协助诊断,避免漏诊、误诊。

Abstract

The patient was a 7-year-old boy admitted with facial edema. Ultrasound indicated moderate pericardial effusion and pleural effusion. Contrast-enhanced chest computed tomography showed indistinct mediastinal structures with mild-to-moderate enhancement, suggestive of a mediastinal space-occupying lesion. Further evaluation with whole-body PET-CT, pathological biopsy of the mediastinal lesion, cytological examination of pleural and pericardial effusions, and immunohistochemistry led to the final diagnosis of isolated myeloid sarcoma. Pathological examination is the gold standard for clinical diagnosis; however, limited sampling sites can result in missed or incorrect diagnoses. Multiple and multi-site sampling should be undertaken according to the clinical context, combined with flow cytometry and immunohistochemistry to assist diagnosis and reduce missed diagnoses and misdiagnoses.

关键词

髓系肉瘤 / 急性髓系白血病 / 心包积液 / 儿童

Key words

Myeloid sarcoma / Acute myeloid leukemia / Pericardial effusion / Child

引用本文

导出引用
杨景晖, 周青梅, 尹雪蓉, . 以纵隔占位首发表现的孤立性髓系肉瘤1例[J]. 中国当代儿科杂志. 2026, 28(3): 346-352 https://doi.org/10.7499/j.issn.1008-8830.2505032
Jing-Hui YANG, Qing-Mei ZHOU, Xue-Rong YIN, et al. A case of isolated myeloid sarcoma initially presenting as a mediastinal mass[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(3): 346-352 https://doi.org/10.7499/j.issn.1008-8830.2505032

参考文献

[1]
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(9): 1151-1159. DOI: 10.1136/annrheumdis-2018-214819 .
[2]
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. DOI: 10.1182/blood-2016-03-643544 .
[3]
Bakst RL, Tallman MS, Douer D, et al. How I treat extramedullary acute myeloid leukemia[J]. Blood, 2011, 118(14): 3785-3793. DOI: 10.1182/blood-2011-04-347229 .
[4]
汤平, 董振坤, 郭荣, 等. 89例髓系肉瘤临床特征及预后因素分析[J]. 中华器官移植杂志, 2021, 42(3): 173-176. DOI: 10.3760/cma.j.cn421203-20200624-00207 .
[5]
Wilson CS, Medeiros LJ. Extramedullary manifestations of myeloid neoplasms[J]. Am J Clin Pathol, 2015, 144(2): 219-239. DOI: 10.1309/AJCPO58YWIBUBESX .
[6]
Kudva R, Monappa V, Solanke G, et al. Myeloid sarcoma: a clinicopathological study with emphasis on diagnostic difficulties[J]. J Cancer Res Ther, 2017, 13(6): 989-993. DOI: 10.4103/0973-1482.220418 .
[7]
马成成, 柴晔. 原发性眼眶髓系肉瘤1例[J]. 临床肿瘤学杂志, 2020, 25(1): 93-96. DOI: 10.3969/j.issn.1009-0460.2020.01.017 .
[8]
Huang XL, Tao J, Li JZ, et al. Gastric myeloid sarcoma without acute myeloblastic leukemia[J]. World J Gastroenterol, 2015, 21(7): 2242-2248. PMCID: PMC4326167. DOI: 10.3748/wjg.v21.i7.2242 .
[9]
刘海燕, 印洪林, 杜军, 等. 粒细胞肉瘤38例临床病理分析[J]. 中华病理学杂志, 2010, 39(3): 172-176. DOI: 10.3760/cma.j.issn.0529-5807.2010.03.006 .
[10]
Claerhout H, Van Aelst S, Melis C, et al. Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study[J]. Eur J Haematol, 2018, 100(6): 603-612. DOI: 10.1111/ejh.13056 .
[11]
中国抗癌协会多原发和不明原发肿瘤专业委员会. 国抗癌协会多原发和不明原发肿瘤诊治指南(2023年版)[J]. 中国癌症杂志, 2023, 33(4): 403-422. DOI: 10.19401/j.cnki.1007-3639.2023.04.011 .
[12]
Yilmaz AF, Saydam G, Sahin F, et al. Granulocytic sarcoma: a systematic review[J]. Am J Blood Res, 2013, 3(4): 265-270. PMCID: PMC3875275.
[13]
Ye F, Zhang H, Zhang W, et al. Clinical characteristics, pathology features and outcomes of pediatric myeloid sarcoma: a retrospective case series[J]. Front Pediatr, 2022, 10: 927894. PMCID: PMC9760868. DOI: 10.3389/fped.2022.927894 .
[14]
Ball S, Knepper TC, Deutsch YE, et al. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations[J]. Cancer, 2022, 128(21): 3880-3887. DOI: 10.1002/cncr.34459 .
[15]
Aboutalebi A, Korman JB, Sohani AR, et al. Aleukemic cutaneous myeloid sarcoma[J]. J Cutan Pathol, 2013, 40(12): 996-1005. DOI: 10.1111/cup.12231 .
[16]
Choi M, Jeon YK, Sun CH, et al. RTK-RAS pathway mutation is enriched in myeloid sarcoma[J]. Blood Cancer J, 2018, 8(5): 43. PMCID: PMC5964090. DOI: 10.1038/s41408-018-0083-6 .
[17]
Hogg G, Severson EA, Cai L, et al. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies[J]. Cancer Genet, 2023, 278-279: 38-49. DOI: 10.1016/j.cancergen.2023.07.006 .
[18]
Willekens C, Renneville A, Broutin S, et al. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations[J]. Leukemia, 2018, 32(9): 2008-2081. DOI: 10.1038/s41375-018-0056-6 .
[19]
Zhao H, Dong Z, Wan D, et al. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma[J]. Sci Rep, 2022, 12(1): 6752. PMCID: PMC9042854. DOI: 10.1038/s41598-022-10831-7 .
[20]
Kashofer K, Gornicec M, Lind K, et al. Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing[J]. Leuk Lymphoma, 2018, 59(2): 501-504. PMCID: PMC5743000. DOI: 10.1080/10428194.2017.1339879 .
[21]
Kantarjian H, Borthakur G, Daver N, et al. Current status and research directions in acute myeloid leukemia[J]. Blood Cancer J, 2024, 14(1): 163. PMCID: PMC11413327. DOI: 10.1038/s41408-024-01143-2 .
[22]
Senapati J, Kadia TM, Daver NG, et al. Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges[J]. Cancer, 2025, 131(7): e35806. DOI: 10.1002/cncr.35806 .
[23]
宋宝全, 宗李红, 孔金玉, 等. 维奈克拉联合去甲基化药物治疗髓系肉瘤5例临床疗效及安全性分析[J]. 临床血液学杂志, 2024, 37(1): 19-22. DOI: 10.13201/j.issn.1004-2806.2024.01.005 .
[24]
Liang Y, Gao J, Wu D, et al. Long-term remission following autologous hematopoietic cell transplantation in a patient with multiple nonleukemic myeloid sarcoma and a review of the literature[J]. Acta Haematol, 2017, 137(3): 117-122. DOI: 10.1159/000455998 .
[25]
Sun J, Zhang YC, Wei J, et al. Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study[J]. Bone Marrow Transplant, 2025, 60(3): 319-325. DOI: 10.1038/s41409-024-02485-y .

脚注

所有作者均声明无利益冲突。

基金

云南省中青年学术和技术带头人后备人才项目(202105AC160030)
云南省“兴滇英才支持计划”名医专项(XDYC⁃MY⁃2022⁃0005)
云南省科技厅—昆明医科大学应用基础研究联合专项(202201AY070001⁃232)
云南省2024年医学高端人才(L⁃2024015)
云南省血液疾病、血栓防治临床医学中心,开放项目(2024YNLCYXZX0235)

版权

版权所有 © 2023中国当代儿科杂志
PDF(2549 KB)
HTML

Accesses

Citation

Detail

段落导航
相关文章

/